Future Science Group

Shalini Prasad and Sriram Muthukumar: non-invasive monitoring technologies by Taylor & Francis Group

Neuromodulatory techniques have risen in profile in recent years, with these groundbreaking therapies now being used to treat a vast range of conditions from Parkinson’s to pain, and obesity to depression. With these techniques now becoming more refined and more readily-available to patients, we spoke to Ali Rezai, a leading neurosurgeon and Director of The Ohio State University Neurological Insti...

In this edition of NCTalks, we’ll be exploring the field of neuroregeneration as part of our latest Spotlight focus on Neuro Central. The limited capacity for repair in the nervous system represents a significant medical challenge - as the field works to address this, we’re learning more and more about innate regeneration, as well as how the regenerative process can be harnessed and exploited to t...

In this podcast discover details of the TONIC trial which has yielded promising response rates in patients with metastatic triple-negative breast cancer treated with nivolumab after induction treatment.

Listen to this podcast to discover more about the UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain). You can view more podcasts plus the latest research, news and interviews at www.oncology-central.com

Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain). You can view more podcasts plus the latest research, news and interviews at www.oncology-central.com

In this edition of NCTalks, Lauren Pulling (Editor, NC) chats with Rachelle Doody, Global Head of Neurodegeneration at Roche. Rachelle tells us about her varied career so far, moving from academia to industry, and discusses challenges in the neurodegenerative field, as well as the current pipeline treatments and diagnostics at Roche. You can view more podcasts, plus the latest news and interviews...

At the ESMO World Congress on Gastrointestinal Cancer 2017 (Barcelona, Spain, 28 June–1 July) we had the pleasure of speaking with Vincenzo Valentini from Gemelli ART (Rome, Italy). Listen to the interview now, to find out about the importance of knowledge based oncology and integrating radiotherapy with other treatment modalities such as surgery.

Brain banks are an essential tool for neuropathological studies, allowing us to answer pressing research questions and test new theories. Recent advances in molecular technologies have further expanded the utility of brain banks, while an aging population is increasing interest in dementia and neurodegenerative disorders. But what are the challenges in maintaining, funding and accessing brain bank...

Whilst at the European Neuro Convention (London, UK, 7–8 June 2017), we caught up with Jean-Pierre Lin, a consultant oediatric neurologist at Guy’s and St Thomas’ NHS Foundation Trust (London, UK), and President of the British Paediatric Neurology Association. In this NCTalks podcast, Jean-Pierre tells us about his clinical and research work, which focuses on movement disorders and neuromodulation...

In this IDHTalks podcast we speak to Mahmoud Ghannoum about the importance of fungi, his work in identifying mycobiome and its implications in health and disease.

At the Alzheimer’s Association International Conference (AAIC; London, UK, 16–20 July 2017), we sat down with Megan Zuelsdorff, University of Wisconsin School of Medicine and Public Health (WI, USA), to hear more about her work on lifetime stress experiences, racial disparities and cognitive health. Part of the Wisconsin Registry for Alzheimer's Prevention (WRAP) Study, Megan and colleagues examin...

Whilst at the Alzheimer’s Association International Conference in London (AAIC; UK, 16–20 July 2017), Lauren Pulling (Editor, Neuro Central) sat down with Kim Mueller, a researcher from the Wisconsin Alzheimer’s Institute (University of Wisconsin-Madison, WI, USA), whose abstract had been highlighted by the Association as one of note. The work presented at AAIC investigated whether early memory de...

Listen to this interview with Philip A Philip from the Karmanos Cancer Center (MI, USA) to discover new strategies and agents for the treatment of pancreatic cancer. You can view more podcasts, plus the latest news and interviews with experts across oncology at www.oncology-central.com

The plenary sessions at Alzheimer’s Association International Conference (AAIC; London, UK, 16–20 July 2017) have featured fantastic talks from leading experts in the field, so far addressing topics including biomarkers, targeting beta-amyloid, genetics, big data and the neurotoxicity of tau. While at the conference, Lauren Pulling (Editor, Neuro Central) sat down with Julie Williams, Professor of...

As part of the Neuro Central Spotlight of neuromodulation, we spoke to Jerrold Vitek, Professor of Neurology and a prominent voice in this ever-expanding field. Dr Vitek is currently the Head of the Neurology Department and Director of the Neuromodulation Research Program at the University of Minnesota (MN, USA), and is the PI for a number of non-human primate and human clinical studies on the neu...

In this podcast, Jade Parker, Editor of Oncology Central speaks to Dirk Arnold. Dirk Arnold is Director of the Dept. Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany. Before taking this position, he was 2010 appointed as Director of the University Cancer Centre in Hamburg (UCCH) and held positions at the University Departments for Oncology and Haematology in Halle-Wittenberg and Ber...

In this NCTalks podcast, Lauren Pulling, Editor of Neuro Central, is joined by Claude Wischik. Prof Wischik is board-certified in psychiatry and a professor of Old Age Psychiatry at the University of Aberdeen (UK). A pioneer in tau research, he discovered the tau protein compositional structure of Alzheimer’s tangles and established that it was possible to dissolve these tangles with pharmaceutica...

How can we bring Parkinson’s disease into the age of personalized medicine? One such approach recently described by Alberto Espay (University of Cincinnati, OH, USA) is to subtype the disease according to the presence of certain biomarkers. This is an approach that he says could “up the ante in our ability to modify the disease”, moving us away from purely dopaminergic strategies that address only...

Whilst at the AAN Annual Meeting (Boston, MA, USA, 22–28 April) last month, we caught up with Regina Katzenschlager, Medical University Vienna and Danube Hospital (both Vienna, Austria), whose research into the use of apomorphine for Parkinson’s disease was highlighted at the conference as one to watch. In this interview, Regina tells us more about the recent Phase III trial, which provided eviden...

Helen McShane discusses her work leading the TB vaccine research program at Oxford University, and shares her thoughts on the challenges facing vaccine development and eradication of this disease.

Listen to this interview with Peter Stern (University of Manchester, UK) to discover more about chemotherapy resistance in acute lymphoblastic leukemia and novel strategies to overcome it.

While at the AAN Annual Meeting (Boston, MA, USA, 22–28 April 2017), we spoke with Dr Michael Alosco, a fellow at Boston University Alzheimer’s Disease and CTE Center(MA, USA), who is currently working on multiple projects looking at chronic traumatic encephalopthy (CTE)in both living and deceased patients. Michael discussed his work, progress towards diagnosis of CTE in life and his thoughts on t...

Reporting from ECCMID17, we spoke to William Irving about his current work on hepatitis C and his thoughts on the future of this field.

Whilst at the American Academy of Neurology’s Annual Meeting (Boston, MA, USA, 22–28 April 2017), we sat down with Michael Pender (University of Queensland, Australia), who was presenting promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis (MS) at the meeting. In this interview, Dr Pender discusses the relationship between MS and the Epstain-Barr...